Not only did Rittmeyer and colleagues (2017) find that atezolizumab resulted in clinically relevant improvement of overall survival vs. docetaxel in previously treated NSCLC, regardless of PD-L1 expression or histology, but that atezolizumab had a favorable safely profile. This evidence concerns the gene CD274 and non-small cell lung carcinoma.